anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
BioAtla · pitchdeck

BioAtla | Investor Presentation Deck | 44 slides

44 pages · 5 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

BioAtla | Investor Presentation Deck | 44 slides

BioAtla · 2023-05
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 24 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 9 hits
— 0/2 slides
100% 2/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides
Market Sizing 7 slides 100% 7/7 slides 100% 7/7 slides · 43 hits
— 0/7 slides
42.9% 3/7 slides 14.3% 1/7 slides 100% 7/7 slides · 13 hits 85.7% 6/7 slides Traction 11 slides 100% 11/11 slides 100% 11/11 slides · 60 hits
— 0/11 slides
54.5% 6/11 slides 18.2% 2/11 slides 100% 11/11 slides · 17 hits 100% 11/11 slides Roadmap 2 slides 100% 2/2 slides 100% 2/2 slides · 7 hits
— 0/2 slides
50% 1/2 slides 50% 1/2 slides 100% 2/2 slides
— 0/2 slides
Team 2 slides 100% 2/2 slides 100% 2/2 slides · 23 hits
— 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides

Slide inventory

44
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a linked-circle diagram to represent the company's core pillars.summarize
Open slide detail
04
other
Open slide detailBeat · Team
05
other
Open slide detailBeat · Team
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to demonstrate the selective binding mechanism.present_solution
Open slide detailBeat · Solution
07
The slide uses a three-column layout to categorize the platform's versatility.present_solution
Open slide detailBeat · Solution
08
The slide uses a Gantt-style visualization to represent clinical trial phases for multiple drug candidates.plan_implementation
Open slide detailBeat · Roadmap
09
transition
Open slide detailBeat · Roadmap
10
The slide uses a structured list format to define the target market and unmet medical need.size_opportunity
Open slide detailBeat · Market Sizing
11
Includes a waterfall plot for partial response and a spider plot for longitudinal tumor change.show_traction
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
12
Includes a spider plot for target lesion change and a Kaplan-Meier survival curve with a summary table.show_traction
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
13
Includes specific clinical trial design details (dosing regimens, patient counts, endpoints).show_traction
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
14
The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.show_traction
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
15
Includes specific clinical trial data (N=73 and N=26) and detailed breakdown of specific adverse events like constipation, neuropathy, and diarrhea.show_traction
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
16
Includes detailed footnotes for data sources and medical abbreviations.size_opportunity
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
17
The chart is a classic waterfall plot used in oncology to show tumor shrinkage/growth.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
18
The slide uses a process-oriented layout to describe clinical trial progression.plan_implementation
Open slide detailBeat · TractionLoop · Cost Of Inaction
19
The chart highlights two specific cohorts (40% and 44% ORR) within a red box to emphasize efficacy in PD-1 failure populations.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
20
Includes waterfall plot (left) and spider plot (right) for patient response data.analyze_data
Open slide detailBeat · TractionLoop · Cost Of Inaction
21
Includes specific clinical trial safety metrics and footnotes regarding data definitions.show_traction
Open slide detailBeat · TractionLoop · Cost Of Inaction
22
NSQ = nonsquamoussummarize
Open slide detail
23
The table details specific drug administration schedules (mg/kg) on days 1, 8, 15, and 22 for different cycle lengths.plan_implementation
Open slide detail
24
Includes abbreviations for LMS, UPS, and NSCLC at the bottom.analyze_data
Open slide detail
25
transition
Open slide detail
26
The slide uses a grid of metrics to establish the total addressable market and the specific sub-segment (2L+ ROR2+ patients) targeted by the company.size_opportunity
Open slide detail
27
The chart displays 'Maximum % Change from Baseline in Sum of Target Lesions'.show_traction
Open slide detail
28
Uses a 2x2 grid layout to present key epidemiological and clinical data points.size_opportunity
Open slide detail
29
The chart is a 'spider plot' or 'swimmer plot' variant showing % change in target lesions over time for two specific patients.show_traction
Open slide detail
30
The slide uses a structured layout to define the patient funnel and clinical need.size_opportunity
Open slide detail
31
The slide presents clinical data points (PR/CR rates) to justify moving to Phase 2.show_traction
Open slide detail
32
The slide uses a side-by-side comparison layout to detail patient cohorts and treatment regimens for different indications.plan_implementation
Open slide detail
33
The table details specific drug administration schedules (mg/kg) for different cycle lengths and days.analyze_data
Open slide detail
34
The table lists specific indications (NSCLC, Melanoma, Head and Neck, Ovarian) and their corresponding dosing schedules (Q2W, 3Q4W) and patient counts (N ~ 20 oanalyze_data
Open slide detail
35
transition
Open slide detail
36
The slide uses a combination of a summary table for clinical data and a dot plot for NHP toxicity data.compare_peers
Open slide detail
37
The slide uses a timeline-based process diagram to show dose escalation and RP2D selection.plan_implementation
Open slide detail
38
transition
Open slide detail
39
The slide uses a before-after framing (problem vs solution) and presents preclinical data (tumor shrinkage and toxicity studies).present_solution
Open slide detail
40
Includes specific dose levels (DL) and priming dose levels (PDL) for the trial.plan_implementation
Open slide detail
41
The slide uses a table structure to represent a timeline of events.plan_implementation
Open slide detailLoop · Why Now
42
The slide uses a linked-circle diagram to represent the company's core pillars.summarize
Open slide detail
43
appendix
Open slide detail
44
The chart illustrates the trade-offs between dosing frequency and concentration levels for an antibody-drug conjugate.analyze_data
Open slide detail